Improving the systemic drug delivery efficacy of nanoparticles using a transferrin variant for targeting

Journal of Controlled Release

Volumn 180, Issue 1, 2014, Pages 33-41

  Chiu, Ricky Y T ^a   Tsuji, Takuma ^b   Wang, Stephanie J ^a   Wang, Juntian ^a   Liu, Christina T ^a   Kamei, Daniel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Cellular association; Intracellular trafficking; Mathematical modeling; Targeted drug delivery; Transferrin

Indexed keywords

CELLULAR ASSOCIATION; DRUG DELIVERY APPLICATIONS; INTRACELLULAR TRAFFICKING; NANOPARTICLE (NPS); TARGETED DRUG DELIVERY; TARGETING LIGANDS; THERAPEUTIC EFFICACY; TRANSFERRIN;

DISEASES; DRUG DELIVERY; EXPERIMENTS; MATHEMATICAL MODELS; NANOPARTICLES; OXALIC ACID;

LIGANDS;

DOXORUBICIN; MACROGOL; NANOPARTICLE; OXALIC ACID; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; POLYSTYRENE; TRANSFERRIN; DRUG CARRIER; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOSOME; HUMAN; HUMAN CELL; HYPOTHESIS; INTERNALIZATION; MATHEMATICAL MODEL; MOLECULARLY TARGETED THERAPY; MOUSE; MTS ASSAY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; MALE; METABOLISM; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; IRON; MALE; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; OXALIC ACID; TRANSFERRIN;

EID: 84896884714     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.01.027     Document Type: Article

References (32)

1. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 2009 659 668
2. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. Heidel, and A. Ribas Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
3. K.K. Sankhala, A.C. Mita, R. Adinin, L. Wood, M. Beeram, S. Bullock, N. Yamagata, K. Matsuno, T. Fujisawa, and A. Phan A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin J. Clin. Oncol. 27 2009 2535
4. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
5. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
6. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 2003 319 328
7. P.T. Yazdi, and R.M. Murphy Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates Cancer Res. 54 1994 6387 6394
8. A.D. Sheftel, A.B. Mason, and P. Ponka The long history of iron in the universe and in health and disease Biochim. Biophys. Acta 1820 2012 161 187
9. P.J. Halbrooks, A.B. Mason, T.E. Adams, S.K. Briggs, and S.J. Everse The oxalate effect on release of iron from human serum transferrin explained J. Mol. Biol. 339 2004 217 226
10. B.J. Lao, W.L. Tsai, F. Mashayekhi, E.A. Pham, A.B. Mason, and D.T. Kamei Inhibition of transferrin iron release increases in vitro drug carrier efficacy J. Control. Release 117 2007 403 412
11. D.J. Yoon, D.S. Chu, C.W. Ng, E.A. Pham, A.B. Mason, D.M. Hudson, V.C. Smith, R.T. MacGillivray, and D.T. Kamei Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins J. Control. Release 133 2009 178 184
12. D.J. Yoon, B.H. Kwan, F.C. Chao, T.P. Nicolaides, J.J. Phillips, G.Y. Lam, A.B. Mason, W.A. Weiss, and D.T. Kamei Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery Cancer Res. 70 2010 4520 4527
13. G. Lake-Bakaar, C.E. Rubio, S. McKavanagh, B.J. Potter, and J.A. Summerfield Metabolism of 125I-labelled trypsin in man: evidence of recirculation Gut 21 1980 580 586
14. L. Mu, and S.S. Feng A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS J. Control. Release 86 2003 33 48
15. S. Hong, P.R. Leroueil, I.J. Majoros, B.G. Orr, J.R. Baker Jr., and M.M. Banaszak Holl The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform Chem. Biol. 14 2007 107 115
16. T. Soukka, H. Harma, J. Paukkunen, and T. Lovgren Utilization of kinetically enhanced monovalent binding affinity by immunoassays based on multivalent nanoparticle-antibody bioconjugates Anal. Chem. 73 2001 2254 2260
17. C. Tassa, J.L. Duffner, T.A. Lewis, R. Weissleder, S.L. Schreiber, A.N. Koehler, and S.Y. Shaw Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles Bioconjug. Chem. 21 2010 14 19
18. A.R. French, and D.A. Lauffenburger Intracellular receptor/ligand sorting based on endosomal retention components Biotechnol. Bioeng. 51 1996 281 297
19. M. Marsh, G. Griffiths, G.E. Dean, I. Mellman, and A. Helenius Three-dimensional structure of endosomes in BHK-21 cells Proc. Natl. Acad. Sci. U. S. A. 83 1986 2899 2903
20. R.L. Roberts, R.E. Fine, and A. Sandra Receptor-mediated endocytosis of transferrin at the blood-brain barrier J. Cell Sci. 104 Pt 2 1993 521 532
21. F. Kilar, and I. Simon The effect of iron binding on the conformation of transferrin. A small angle X-ray scattering study Biophys. J. 48 1985 799 802
22. F. Kilar, and S. Hjerten Separation of the human transferrin isoforms by carrier-free high-performance zone electrophoresis and isoelectric focusing J. Chromatogr. 480 1989 351 357
23. A. Dautry-Varsat, A. Ciechanover, and H.F. Lodish pH and the recycling of transferrin during receptor-mediated endocytosis Proc. Natl. Acad. Sci. U. S. A. 80 1983 2258 2262
24. H.S. Yoo, J.E. Oh, K.H. Lee, and T.G. Park Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release Pharm. Res. 16 1999 1114 1118
25. H.S. Yoo, and T.G. Park Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer J. Control. Release 70 2001 63 70
26. R. Lin, L. Shi Ng, and C.H. Wang In vitro study of anticancer drug doxorubicin in PLGA-based microparticles Biomaterials 26 2005 4476 4485
27. F. Tewes, E. Munnier, B. Antoon, L. Ngaboni Okassa, S. Cohen-Jonathan, H. Marchais, L. Douziech-Eyrolles, M. Souce, P. Dubois, and I. Chourpa Comparative study of doxorubicin-loaded poly(lactide-co-glycolide) nanoparticles prepared by single and double emulsion methods Eur. J. Pharm. Biopharm. 66 2007 488 492
28. J. Park, P.M. Fong, J. Lu, K.S. Russell, C.J. Booth, W.M. Saltzman, and T.M. Fahmy PEGylated PLGA nanoparticles for the improved delivery of doxorubicin Nanomedicine: NBM 5 2009 410 418
29. R.Y.T. Chiu, T. Tsuji, C.T. Liu, A.B. Mason, and D.T. Kamei Investigation of systemic drug delivery applications for a transferrin variant Books of Abstracts: 2011 BMES Annual Meeting, Hartford, CT October 12-15, 2011
30. R.Y.T. Chiu, K.M. Mayle, T. Tsuji, C.T. Liu, R.J. Lamm, J. Wang, A.B. Mason, and D.T. Kamei Enhancing the delivery efficacy of drug-encapsulated nanoparticles using a transferrin variant Books of Abstracts: 243rd American Chemical Society National Meeting & Exposition, San Diego, CA March 25-29, 2012
31. R.Y.T. Chiu, T. Tsuji, C.T. Liu, J. Wang, A.B. Mason, and D.T. Kamei Engineered transferrin for the targeted delivery of drug-loaded nanoparticles Books of Abstracts: 2012 BMES Annual Meeting, Atlanta, GA Oct 24-27, 2012 Biomedical Engineering Society
32. L.C. Wu, L.W. Chu, L.W. Lo, Y.C. Liao, Y.C. Wang, and C.S. Yang Programmable cellular retention of nanoparticles by replacing the synergistic anion of transferrin ACS Nano 7 2013 365 375